Clinical influence of exercise therapy on sarcopenia in patients with chronic pancreatitis: a study protocol for a randomised controlled trial. Issue 1 (4th January 2018)

• Record Type: Journal Article
• Authors: Yoh, Kazunori; Nishikawa, Hiroki; Enomoto, Hirayuki; Iwata, Yoshinori; Ishii, Akio; Yuri, Yukihisa; Ishii, Noriko; Miyamoto, Yuho; Hasegawa, Kunihiro; Nakano, Chikage; Takata, Ryo; Nishimura, Takashi; Aizawa, Nobuhiro; Sakai, Yoshiyuki; Ikeda, Naoto; Takashima, Tomoyuki; Iijima, Hiroko; Nishiguchi, Shuhei
• Is Part Of: BMJ open gastroenterology. Volume 5:Issue 1(2018)
• Publication Date: 2018-01-04
• Subjects: abdominal pain -- chronic pancreatitis -- nutrition -- nutritional status; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/bmjgast-2017-000190
• Languages: English
• ISSNs: 2054-4774

Abstract

Abstract : Introduction and purpose: Chronic pancreatitis (CP) involves progressive inflammatory changes to the pancreas and can lead to permanent structural damage and impairment of both endocrine and exocrine functions. Current reports highlight a rise in the incidence and prevalence of CP. However, there is limited data currently available concerning patients with CP undergoing exercise therapy (ET). We aim to prospectively examine the influence of ET on sarcopenia in patients with CP. Methods and analysis: A detailed evaluation of the nutritional condition and the daily physical activities of each participant will be conducted prior to entering the study. Our patients will be randomly allocated to either: (1) the ET group or (2) the control group. In the ET group, our patients with CP will receive nutritional guidance once a month. The patients with CP will also be instructed to perform exercises with > 3 metabolic equivalents (mets; energy consumption in physical activities/resting metabolic rate) for 60 min/day and to perform exercises >23 mets/week. The primary end point will be an improvement in sarcopenia, defined as an increase in muscle mass and muscle strength, at 3 months postrandomisation. A comparison of the amelioration of sarcopenia in the two groups will be undertaken. Ethics and dissemination: The Institutional Review Board at Hyogo College of Medicine approved this study protocol (approval no. 2766). Final data will be publicly announced. A report releasing the study results will be submitted for publication to an appropriate journal. Trial registration number: UMIN000029263 ; Pre-results. No patient is registered at the submission of our manuscript.